Yujiro Hata, Ideaya Biosciences CEO
Ideaya stock slashed after GSK punts an option
After two years, GSK is out on a partnered program with Ideaya Biosciences — and investors are not pleased.
The synthetic lethality-focused oncology player reported early …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
